T-cell proliferation assays, lymphocyte subsets, and vaccination responses before and after GT
| . | Before GT . | After GT . | Healthy control ranges for 3-d stimulation . |
|---|---|---|---|
| T-cell proliferation | |||
| Spontaneous (cpm) | 103 | 115* | |
| PHA (cpm) | 2490 | 50 349* | 18 906-417 388 |
| aCD3 (cpm) | 226 | 22 699* | 187-122 682 |
| aCD3/aCD28 (cpm) | 2186 | 52 068* | 1202-213 904 |
| Lymphocyte subsets | |||
| Total lymphocytes (×109/mL) (normal range: 1.0-2.8) | 0.572 | 2.251† | 1.469/1.11§ |
| CD3 (×109/mL) (normal range: 0.7-2.1) | 0.518 | 1.389† | 0.789/0.723§ |
| CD4 (×109/mL) (normal range: 0.3-1.4) | 0.414 | 0.62† | 0.407/0.409§ |
| CD8 (×109/mL) (normal range: 0.2-0.9) | 0.105 | 0.408† | 0.252/0.23§ |
| CD19 (×109/mL) (normal range: 0.1-0.5) | 0.027 | 0.408† | 0.407/0.409§ |
| Vaccination responses | |||
| Total pneumococcal titres (mg/L) (protective levels >20 mg/L) | On immunoglobulin replacement therapy | 4‡ | 43|| |
| Pneumococcus serotype-specific responses (protective levels >0.35 mg/L) | On immunoglobulin replacement therapy | ND‡ | Protective responses against 3/13 serotypes|| |
| Tetanus toxoid (IU/mL) (protective levels: 0.1-0.7) | On immunoglobulin replacement therapy | 0.14‡ | 2.51|| |
| . | Before GT . | After GT . | Healthy control ranges for 3-d stimulation . |
|---|---|---|---|
| T-cell proliferation | |||
| Spontaneous (cpm) | 103 | 115* | |
| PHA (cpm) | 2490 | 50 349* | 18 906-417 388 |
| aCD3 (cpm) | 226 | 22 699* | 187-122 682 |
| aCD3/aCD28 (cpm) | 2186 | 52 068* | 1202-213 904 |
| Lymphocyte subsets | |||
| Total lymphocytes (×109/mL) (normal range: 1.0-2.8) | 0.572 | 2.251† | 1.469/1.11§ |
| CD3 (×109/mL) (normal range: 0.7-2.1) | 0.518 | 1.389† | 0.789/0.723§ |
| CD4 (×109/mL) (normal range: 0.3-1.4) | 0.414 | 0.62† | 0.407/0.409§ |
| CD8 (×109/mL) (normal range: 0.2-0.9) | 0.105 | 0.408† | 0.252/0.23§ |
| CD19 (×109/mL) (normal range: 0.1-0.5) | 0.027 | 0.408† | 0.407/0.409§ |
| Vaccination responses | |||
| Total pneumococcal titres (mg/L) (protective levels >20 mg/L) | On immunoglobulin replacement therapy | 4‡ | 43|| |
| Pneumococcus serotype-specific responses (protective levels >0.35 mg/L) | On immunoglobulin replacement therapy | ND‡ | Protective responses against 3/13 serotypes|| |
| Tetanus toxoid (IU/mL) (protective levels: 0.1-0.7) | On immunoglobulin replacement therapy | 0.14‡ | 2.51|| |